Assay News and Research

RSS

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Evotec and Genentech sign drug discovery deal

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group (SWX:RO) (SIX:ROG) (Pink Sheets:RHHBY), to discover novel small molecule therapeutics.

10 May 2010

Creator of California Tay-Sachs Disease Prevention Program among the honorees

A mere 40 years ago, parents didn't know they were carriers of the Tay-Sachs disease until after they'd given birth to a child with this fatal genetic disorder.

7 May 2010

Nanosphere reports $0.8 million revenue for first-quarter 2010

Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

AMRI first-quarter total revenue down 9% to $49.3 million

AMRI today reported financial and operating results for the first quarter ended March 31, 2010.

5 May 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.

4 May 2010

FDA grants market clearance for Illumina's BeadXpress system for multiplex genetic analysis

Illumina, Inc. today announced that the U.S. Food and Drug Administration has granted 510(k) market clearance for the company's BeadXpress system for multiplex genetic analysis.

From Illumina, Inc. 4 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Department of Molecular Oncology, Dave S. B. Hoon, Ph.D., Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG's qNPA technology in classical surgical pathology samples.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

FDA approves Abbott Prism Chagas test to screen blood, tissue and organ donors for T. cruzi

The U.S. Food and Drug Administration today approved a second test to screen blood, tissue and organ donors for a blood-borne parasite, Trypanosoma cruzi that causes Chagas disease, a serious and potentially fatal parasitic infection.

3 May 2010

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

Gen-Probe Incorporated today reported financial results for the first quarter of 2010, highlighted by $135.4 million of total revenues and earnings per share of $0.48 on both a non-GAAP and GAAP basis.

30 Apr 2010

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

iPierian, Inc., the leading company focused on creating new therapeutics discovered using cellular reprogramming and directed differentiation of patient cells, today announced that it has been awarded a three-year $1.5 million "Basic Biology Award" from the California Institute of Regenerative Medicine.

30 Apr 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

Study results from US Military Malaria Vaccine Program announced

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that the US Military Malaria Vaccine Program presented results of its study using the Biojector2000 with a recombinant DNA vaccine at two recent conferences. A Cooperative Research and Development Agreement was signed with the Navy in April 2009 to work together on the study.

28 Apr 2010

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

RedPath Integrated Pathology, Inc., a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced today that it has entered into a binding agreement to be acquired by ExonHit Therapeutics, S.A., a leading French diagnostics and therapeutics biotech company for an upfront payment of $12.5M in cash and $10M in stock, and starting in 2012, subsequent additional payment up to $9.5M dependent on the achievement of sales targets.

27 Apr 2010

ATCC introduces CRMs for method validation and method-performance verification

ATCC announces the launch of Certified Reference Materials, issued under ISO Guide 34 and ISO 17025:2005 accredited and ISO 9001:2008 certified laboratories. As a certified reference material producer, the combined accreditations demonstrate the highest level of quality assurance, accuracy and traceability for ATCC customers.

26 Apr 2010

SQI Diagnostics signs development agreement with Silliker

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that it has entered into a development agreement with Silliker, Inc., a leading internationally accredited company dedicated to improving nutrition, food safety and quality, for the commercialization of a botulism toxin panel that will run on SQI's SQiDman analytical system.

26 Apr 2010

Study confirms utility of Oxford Immunotec's T-SPOT.TB assay in identifying latent TB infection

The authors of a recent peer-reviewed study published in the International Journal of Tuberculosis and Lung Disease confirmed the high specificity of the T-SPOT.TB assay.

26 Apr 2010

Assay News and Research

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Evotec and Genentech sign drug discovery deal

Creator of California Tay-Sachs Disease Prevention Program among the honorees

Nanosphere reports $0.8 million revenue for first-quarter 2010

AMRI first-quarter total revenue down 9% to $49.3 million

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

FDA grants market clearance for Illumina's BeadXpress system for multiplex genetic analysis

QIAGEN reports 20% revenue growth in first quarter 2010

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

FDA approves Abbott Prism Chagas test to screen blood, tissue and organ donors for T. cruzi

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

Study results from US Military Malaria Vaccine Program announced

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

ATCC introduces CRMs for method validation and method-performance verification

SQI Diagnostics signs development agreement with Silliker

Study confirms utility of Oxford Immunotec's T-SPOT.TB assay in identifying latent TB infection

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News